Summary of Conference Call Records Industry Overview - The focus is on the oral GLP-1 drug "O Drug" and its related supply chain, with companies like Kanglong Chemical, WuXi AppTec, Kelun Pharmaceutical, and Chengda Pharmaceutical receiving clear orders for production [1][2] - The global biotech sector is shifting from monetary policy influences to breakthroughs in technology and patent cliffs, with expectations for a similar upward cycle as seen in 2014/2018 driven by GLP-1 products and M&A demands [1][3] - The domestic innovative drug sector is showing positive fundamentals, with business development (BD) totals reaching levels comparable to the first half of 2025, indicating a transition from losses to profitability for many companies [1][4] Key Points on "O Drug" - "O Drug" is expected to receive FDA approval for weight loss indications in April 2026, with its application submitted at the end of 2025 [2] - A head-to-head study in February 2026 showed "O Drug" outperforming oral semaglutide in reducing glycated hemoglobin and weight loss [2] - The product is currently in a pre-approval stocking phase, which is anticipated to boost API and CDMO orders for companies involved in its production [2] Market Dynamics - The current macro environment for the global biotech industry is driven by technological breakthroughs and the impending patent cliffs faced by large pharmaceutical companies, leading to increased M&A activity [3][4] - Historical data indicates that biotech indices have continued to rise even during interest rate hikes, suggesting a resilient market [4] Investment Opportunities - The investment strategy emphasizes selecting companies transitioning from biotech to biopharma, with Kangfang Biologics and Kangnuo Pharmaceutical highlighted for their expected sales growth and pipeline flexibility [1][7] - A tiered investment approach is recommended: - **Low-risk, high-certainty companies**: Kangfang, Kangnuo, and Fuhong Hanlin are expected to have significant growth potential [1][7] - **High-flexibility companies**: Companies like Junshi Biosciences and Xinlitai are noted for their potential to double or triple in value based on performance [1][7] - **Stable companies**: Companies such as Baiji Shenzhou and Xinda Biopharmaceuticals are recommended for long-term holding with expected growth of 30% to 50% [1][7] Emerging Technologies - The core focus for Chinese innovative drugs going abroad in 2026 includes dual antibodies (e.g., PD-1/VEGF) and ADCs, with significant clinical data expected to validate their market potential [6] - New technologies such as TCE dual antibodies and small nucleic acid drugs are also highlighted for their promising development and potential for international transactions [6] Conclusion - The innovative drug sector is positioned for growth, supported by favorable policies and a recovering market valuation after significant corrections in leading company stock prices [5][6]

Investment Rating - The industry rating is "Outperform the Market" [7][70] Core Insights - The enthusiasm for innovative drugs is returning, with a focus on investment opportunities in the Eli Lilly oral weight loss drug supply chain [3][5] - Eli Lilly's oral weight loss drug Orforglipron is expected to receive FDA approval in April 2026, which is a key catalyst for the industry [5][19] - The report emphasizes the importance of innovative drugs and medical devices as the main themes for the pharmaceutical industry in 2026, with a focus on revenue realization and high-growth performance [6][30] Summary by Sections 1. Weekly Performance of Recommended Pharmaceutical Portfolio - The recommended portfolio outperformed the pharmaceutical index by 4.9 percentage points and the overall market by 7.8 percentage points [14][15] 2. Eli Lilly's Oral Weight Loss Drug Orforglipron Approval - Orforglipron has shown superior results in the ACHIEVE-3 study compared to oral semaglutide, with significant improvements in A1C reduction and weight loss [20][21] - The drug is expected to be launched in 2026, with a focus on investment opportunities in the supply chain, including companies like WuXi AppTec and Kelun Pharmaceutical [5][25] 3. Weekly Market Review and Hotspot Tracking (March 23-27, 2026) - The CITIC Pharmaceutical Index fell by 1.4% but outperformed the CSI 300 Index by 2.9 percentage points [4][30] - The top-performing stocks included Meinuohua (+40.7%), Wanbangde (+38.8%), and Fuxiang Pharmaceutical (+27.6%) [43][49] - The report highlights the recovery of innovative drug sentiment and the expected significant returns in the upcoming months due to upcoming conferences and strong revenue growth [6][30]

Core Viewpoint - The article discusses the significant upgrade of oral semaglutide, which is redefining the competitive landscape in the GLP-1 drug market by enhancing the formulation and delivery system, thus raising the bar for future competitors [2][3][5][7]. Group 1: Product Upgrade - The new formulation of oral semaglutide features optimized dosages of 1.5 mg, 4 mg, and 9 mg, compared to the original 3 mg, 7 mg, and 14 mg, indicating improved absorption efficiency at lower doses [2][3]. - The upgrade is not merely a reduction in dosage but reflects advancements in the formulation design and delivery efficiency, achieving equivalent exposure with lower doses [2][3]. Group 2: Delivery System Challenges - Oral peptide drugs face significant challenges, including degradation in the gastrointestinal environment, destruction by digestive enzymes, and poor permeability through epithelial barriers [3]. - The delivery strategy centered around SNAC has been crucial in enhancing the absorption conditions in the stomach and facilitating effective trans-mucosal penetration, significantly improving the oral bioavailability of semaglutide [3]. Group 3: Competitive Landscape - The complexity of replicating the oral semaglutide delivery system makes it more challenging for generic manufacturers compared to injectable forms, as the core logic of the delivery platform remains difficult to duplicate [5]. - The proactive upgrade of the formulation by the original manufacturer serves as a defensive strategy, enhancing product competitiveness and raising the entry barriers for potential competitors [5][7]. Group 4: Industry Implications - The upgrade of oral semaglutide signals a shift in the peptide drug industry, where the competitive edge increasingly relies on formulation platforms and delivery capabilities rather than just the active molecule itself [7]. - For generic drug companies, the rules of engagement have changed, making it more complex to enter the market, as the focus will now be on achieving convenience, stability, and efficiency in drug delivery [7].

Regulatory Updates - In 2025, the National Medical Products Administration (NMPA) received 457 special approval applications for innovative medical devices, with 104 approved for special review and 38 priority applications, of which 26 were granted priority approval [1] - By the end of 2025, 475 traditional Chinese medicine production bases passed inspections, covering nearly 1.24 million acres and providing 101 types of Chinese medicinal materials for 215 production enterprises [2] Company Announcements - Shanghai Pharmaceuticals announced that its pregabalin capsules received a drug registration certificate from the Philippines, with a total sales amount of $13.37 million for three specifications [2] - Jiukang Bio received a medical device registration certificate for its albumin assay kit, valid until February 12, 2031 [3] Clinical Research - Eli Lilly's orforglipron demonstrated superior efficacy in glycemic control and weight loss compared to oral semaglutide in a head-to-head study involving 1,698 participants [4][5] - The study results were published in The Lancet, indicating significant improvements in A1C and weight reduction with orforglipron [5] Financial Performance - Baili Tianheng reported a net loss of 1.051 billion yuan for 2025, a significant decline from the previous year, with total revenue of 2.520 billion yuan, down 56.72% [8] - Junshi Biosciences achieved a total revenue of 2.498 billion yuan in 2025, a year-on-year increase of 28.23%, but reported a net loss of 874 million yuan [8] - Yifang Bio reported a net loss of 317 million yuan for 2025, with total revenue of 37.3253 million yuan, down 77.89% [9] - Nanmo Bio's total revenue for 2025 was 421.2586 million yuan, up 10.50%, with a net profit increase of 399.29% to 32.4313 million yuan [10]

Group 1 - Eli Lilly announced the results of the first head-to-head study of its oral GLP-1 receptor agonist orforglipron, showing a significant reduction in HbA1c levels compared to oral semaglutide [2] - In the study, the orforglipron 36mg group achieved a 2.2% reduction in HbA1c, while the oral semaglutide 14mg group achieved a 1.4% reduction [2] - The orforglipron group also experienced an average weight loss of 8.9kg (9.2%), compared to 5.0kg (5.3%) in the semaglutide group, representing a 73.6% higher relative weight loss [2] Group 2 - Oral semaglutide, developed by Novo Nordisk, is the first approved oral GLP-1 drug, with both glycemic control and weight loss indications approved in the US market [3] - The global GLP-1 development race is entering its "second half," with pharmaceutical companies focusing on next-generation innovative weight loss therapies, including oral small molecules and long-acting formulations [3] - Novo Nordisk announced a significant price reduction for semaglutide in the US, effective January 1, 2027, with the monthly cost dropping to $675 [3] Group 3 - In China, the price of oral semaglutide has also been reduced, with the 7mg version dropping from 600 yuan to 480 yuan per box, and the 3mg version from 313.66 yuan to 250.92 yuan per box, reflecting a decrease of around 20% [4]

Core Insights - Eli Lilly's orforglipron has demonstrated superior efficacy compared to oral semaglutide in a head-to-head study for type 2 diabetes management, showing a 2.2% reduction in A1C levels versus 1.4% for semaglutide [1][2] - The study also indicated that participants taking orforglipron experienced an average weight loss of 8.9 kg (9.2%), compared to 5.0 kg (5.3%) for those on semaglutide, representing a 73.6% higher relative weight loss [1][2] Company Developments - Orforglipron, discovered by a collaboration between Chinese and foreign pharmaceutical companies, has been submitted for regulatory approval in over 40 countries, with a decision expected in the U.S. by Q2 2026 for obesity indications [2] - Oral semaglutide, developed by Novo Nordisk, is the first approved oral GLP-1 medication, with both glycemic control and weight loss indications approved in the U.S. and glycemic control approved in China [2] Industry Trends - The GLP-1 sector is experiencing a competitive landscape, with a focus on oral formulations, ultra-long-acting agents, and multi-target agonists to enhance patient experience and treatment efficacy [2] - Oral medications are perceived to have advantages over injectable GLP-1 drugs in terms of convenience and patient acceptance [2] Pricing Strategies - Novo Nordisk has announced significant price reductions for oral semaglutide in various markets, including a planned price drop in the U.S. to $675 per month starting January 1, 2027 [2] - In China, recent price adjustments have seen the cost of oral semaglutide drop by approximately 20%, with the 7 mg formulation reduced from 600 RMB to 480 RMB per box [3]

Group 1 - The core finding of the article is that Eli Lilly's Orforglipron outperformed oral semaglutide in the Achieve-3 study, achieving all primary and key secondary endpoints [1] Group 2 - Orforglipron demonstrated significant efficacy in the study, indicating its potential as a competitive treatment option in the diabetes market [1] - The results may influence future treatment guidelines and market dynamics for diabetes medications [1] - Eli Lilly's advancements in this area could enhance its market position and drive growth in its pharmaceutical portfolio [1]

Core Viewpoint - Novo Nordisk is strategically restructuring its global supply chain for oral weight loss drug Wegovy, focusing on managing production capacity, tariffs, and market timing simultaneously [4][6]. Group 1: Supply Chain Strategy - Novo Nordisk is investing in the Athlone facility in Ireland, acquiring it for approximately $91 million, to serve as a global supply center for non-US markets, allowing for quicker ramp-up of production [4][6]. - The Athlone facility is not a greenfield project but an existing industrial asset, which significantly reduces the time and cost associated with building new production lines [4][6]. - The company is also expanding its Clayton facility in North Carolina with an investment of $4.1 billion, which will double its sterile filling and finished product capacity, creating around 1,000 new jobs [7]. Group 2: Market Demand and Competition - The demand for oral Wegovy is rapidly increasing, with prescriptions climbing from approximately 3,071 in the first four days post-launch to over 240,000 by early February [6]. - Eli Lilly is also ramping up its production capabilities for its oral GLP-1 drug, orforglipron, with a pre-launch inventory of about $1.5 billion and multiple manufacturing sites planned across the U.S. [8][10]. - The competition in the oral weight loss drug market is intensifying, with production capacity becoming a critical factor in determining market share and pricing strategies [10]. Group 3: Trade and Tariff Considerations - Ireland's selection as a manufacturing hub is influenced by the uncertainties surrounding trade and tariffs, prompting companies to stock inventory in target markets to mitigate risks from potential policy changes [9][10]. - In May 2025, Ireland's pharmaceutical exports reached approximately €13.7 billion, a 73.9% increase year-on-year, highlighting the country's growing importance in the global pharmaceutical supply chain [9][10].

Core Insights - Novo Nordisk reported a 6% increase in sales in Danish kroner for 2025, and a 10% increase at constant exchange rates, reaching 309.1 billion Danish kroner [1] Sales Performance - Sales in the Greater China region grew by 5% at constant exchange rates, primarily driven by the growth in obesity treatment products [1] - Sales in the rare disease segment in Greater China increased by 84% at constant exchange rates, mainly due to growth in the rare blood disorders area [1] Regulatory Approvals and Product Updates - The China National Medical Products Administration approved the cardiovascular indication for Novo's drug, Ozempic, based on the SELECT study [1] - Novo Nordisk submitted data from the SOUL cardiovascular outcomes trial for oral semaglutide to update the label for its drug, Rybelsus, for type 2 diabetes patients [1] Shareholder Returns - The board proposed a dividend of 7.95 Danish kroner per share for the end of 2025, totaling 11.70 Danish kroner for the entire year [1] - A new share buyback program of up to 15 billion Danish kroner was also announced [1]

Core Viewpoint - Zealand Pharma is seeking partners for innovative weight loss treatments that target the brain directly, emphasizing the central nervous system's role in metabolic regulation and immune response [4][6]. Group 1: Strategic Collaborations - Zealand Pharma is exploring collaborations to develop therapies that can cross the blood-brain barrier, with a focus on "shuttle technology" to safely deliver drugs to the brain [4][6]. - The company has engaged in discussions with Roche and other institutions regarding brain-targeted research, acknowledging the high difficulty of these projects but recognizing their potential to fundamentally change metabolic disease treatment [6]. - Zealand recently announced a $20 million upfront payment to OTR Therapeutics, with a total potential of $30 million, to leverage its oral small molecule platform for discovering new metabolic disease therapies [8]. Group 2: Product Pipeline and Development - Zealand's pipeline includes the promising drug petrelintide, which is expected to show an average weight loss of 8.6% over 16 weeks in its Phase II trial, with results anticipated in mid-2026 [9]. - The company is also advancing the dual agonist survodutide in Phase III trials for obesity and MASH, alongside other projects targeting short bowel syndrome and congenital hyperinsulinemia [9]. - Zealand's strategy includes a roadmap titled "Metabolic Frontier 2030," aiming to launch five products by 2030, indicating a long-term vision for growth in the metabolic disease sector [9]. Group 3: Market Position and Future Outlook - Zealand's entry into oral small molecule collaborations is seen as a risk mitigation strategy amid rising competition in the oral weight loss drug market, particularly with Novo Nordisk's oral semaglutide awaiting regulatory approval [8]. - The company believes it has sufficient research capabilities and financial reserves to navigate uncertainties in the market, positioning itself for continuous iteration and improvement [9]. - Zealand's future innovations may include improving insulin sensitivity unrelated to weight and eventually directly modulating brain receptors, showcasing a commitment to long-term health impact [10].